A Study of BBI608 in Adult Patients With Advanced Malignancies
This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.
Cancer, Advanced Malignancies
DRUG: BBI608
Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Assessment of safety of BBI608 given in monotherapy to patients with advanced malignancies by reporting of adverse events and serious adverse events, Adverse events will be assessed at baseline, while the participant is taking BBI608, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months.
This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.